oral lichen planus
Conditions
Interventions
Sponsors
Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 75 years = Age= 18 years, and sign the informed consent form ; 2. Patients who meet the erosive OLP criteria: (OLP confirmed according to medical history, clinical manifestations and pathological examination, REU=4.5 and U=1) and cannot tolerate or refuse to use hormones; 3. Consent to the use of effective contraceptive methods during the trial; 4. The general condition can tolerate the treatment plan formulated.
Exclusion criteria
Exclusion criteria: 1. Individuals with other confirmed oral mucosal diseases; 2. Oral lichen planus is classified as asymptomatic reticulate type, or oral lichen planus with severe abnormal hyperplasia or cancer; 3. Patients with abnormal liver and kidney function : active liver disease or abnormal liver function, ALT, AST, TBIL is more than 1.5 times the upper limit of normal value, renal function damage, serum creatinine = 133mmol / L ( 1.5mg / dL ); 4. Subjects with white blood cells < 3.0 × 10^9 / L, or clear anemia ( hemoglobin < 80g / L ) or combined with hemolytic anemia, or platelet < 80 × 10^9 / L, or other blood system diseases ; 5. Pregnant or lactating women 6. Serious, uncontrolled systemic diseases, such as blood system diseases, ventricular dysfunction with or without a history of congestive heart failure, or any accompanying conditions, researchers believe that affect the treatment and outcome evaluation, or can not ensure the completion of this study ; 7. The estimated survival time was < 3 months. 8. During the 12 months prior to Visit 1, there was alcoholism, drug dependence, and any investigator 's judgment that the subject could not complete the entire study or that there was a clear risk for the subject to participate in the study; 9. Allergic to iguratimod; 10. There are a variety of other situations where researchers believe that they can not join the clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| REU score; | — |
Secondary
| Measure | Time frame |
|---|---|
| REU score;effective index;VAS (visual analogue scale) score; | — |
Countries
China
Contacts
Public ContactShen Xuemin
Department of Oral Medicine, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed